Vera Therapeutics, Inc. (VERA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
8000 Marina Boulevard
Brisbane, CA 94005
United States of America (the)
Phone
650 770 0077
Website
Sector
Healthcare
Industry
Biotechnology
Employees
152
First IPO Date
May 14, 2021
| Name | Title | Pay | Year Born |
| Marshall Fordyce | Founder, President, Chief Executive Officer & Director | 1.21M | 1975 |
| William D. Turner | Chief Regulatory Officer | 737,880 | 1967 |
| Sean Grant | Chief Financial Officer | 793,920 | 1985 |
| Robert Brenner | Chief Medical Officer | 797,040 | 1968 |
| David L. Johnson | Chief Opearating Officer | 798,600 | 1970 |
| Debra Charlesworth | Vice President of Corporate Communications | 0 | N/A |
| Emma Haywood | Vice President of Marketing | 0 | N/A |
| S. Sandra Park | Senior Vice President of Legal, Healthcare,Commercial Law, Compliance & Operations | 0 | N/A |
| Jane Wright-Mitchell | Chief Legal Officer & Secretary | 0 | 1969 |
| Joseph R. Young | Senior Vice President of Finance & Chief Accounting Officer | 0 | 1972 |
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.